Results 141 to 150 of about 1,586,237 (267)

A Trp574–Leu substitution confers resistance to three classes of acetolactate synthase inhibitors in Australian brome grass (Bromus diandrus)

Pest Management Science, Volume 82, Issue 10, Page 9437-9443, October 2026.
Target‐site based imidazolinone resistance in brome grass was found to be conferred by a mutation at position 574 in the ALS gene and to severely impact the efficacy of the herbicide Intervix®, a co‐formulation of imazamox and imazapyr. Abstract BACKGROUND Brome grass (Bromus diandrus) is a prevalent weed in southern Australian cropping regions which ...
Roberto Busi, Danica Goggin, Nick Eyres, Fabian Runge, Aimone Porri, Ken Flower   +5 more
wiley   +1 more source

Pro‐197 mutations confer resistance to thiencarbazone but not to foramsulfuron in ALS‐resistant Poa annua populations

Pest Management Science, Volume 82, Issue 10, Page 10134-10146, October 2026.
Foramsulfuron remains effective on Pro‐197 Poa annua, but co‐formulation with thiencarbazone reduces efficacy due to limited activity and antagonism. Therefore, foramsulfuron + thiencarbazone should be used in fields without ALS‐resistant weeds to ensure effective in‐crop control.
Vijaya Bhaskar Alwarnaidu Vijayarajan, Iniya Vijayakumar, Rafa Ruiz‐Partida, Fabian Runge, Joel Torra, Jorge Lozano‐Juste, Patrick Dermot Forristal   +6 more
wiley   +1 more source

Effectiveness and Safety of Fixed‐Dose Combination Metformin and Empagliflozin in Type 2 Diabetes: A Prospective, Multicenter, Real‐World Study From China

Journal of Diabetes, Volume 18, Issue 10, October 2026.
This large‐scale real‐world Chinese study demonstrates glycemic clinical control rates (HbA1c > 7%) at baseline and 6 months across key subgroups, including age, baseline HbA1c, body mass index, and treatment regimen. In this prospective real‐world study of fixed‐dose combination metformin and empagliflozin in Chinese patients with type 2 diabetes ...
Weijian Ke, Yinghong Kong, Songbo Fu, Liyun Wang, Ying Pan, Shao Zhong, Yanhua Jiang, Hui Chen, Xuehua Jiao, Fuxing Sha, Liwu Xu, Wei Shao, Fenghua Lan, Xiaoli Chen, Bo Yan, Guangju Zhou, Ping Shi, Fen Li, Huike He, Hong Li, Guangwu Zhang, Hongyu Duan, Fang Wang, Weikun Gong, Yuxiao Bai, Bin Wang, Xin Mou, Liying He, Wukun Ma, Junhua Song, Juan Zheng, Xiaosu Bai, Xiaosi Li, Xin Yan, Yanqiu Wang, Zhenhua Wang, Juan Yuan, Wei Lu, Yuan Liang, Yufan Wang, Fenjuan Xu, Xuefeng Li, Xuan Lin, Hongbin Zhu, Lingling Xu, Xiaojia Lou, Lingxiao Wang, Lijuan Cui, Lijun Wang, Hua Qian, Yuwen Shi, Yanbing Li   +51 more
wiley   +1 more source

The Crosstalk Between Diabetes and Alzheimer's Disease: A Molecular Perspective

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 4, October 2026.
Increasing evidence indicates an association between type 2 diabetes mellitus and Alzheimer’s disease, contributing to the proposed concept of AD as “type 3 diabetes.” Shared biological features such as impaired insulin signaling, chronic inflammation, mitochondrial dysfunction, and oxidative stress have been observed in both T2DM and AD.
Deniz Catakli, Ozlem Ozen‐Basoglu, Ebru Busra Tuncgovde, Gonen Ozsarlak‐Sozer   +3 more
wiley   +1 more source

Efficacy and Hypoglycaemia Outcomes With Once‐Weekly IcoSema Versus Comparators in Individuals With Type 2 Diabetes by Kidney and Liver Function: A Post Hoc Analysis of the COMBINE 1–3 Trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9607-9620, October 2026.
ABSTRACT Aims This post hoc analysis of COMBINE 1–3 assessed efficacy and hypoglycaemia outcomes with IcoSema (once‐weekly combination therapy of basal insulin icodec and semaglutide [a glucagon‐like peptide‐1 analogue]) versus comparators in adults with type 2 diabetes (T2D) by kidney and liver function subgroups.
Linong Ji, Jonas Dahl Andersen, Malik Benamar, Paola Ponzani, A. G. Unnikrishnan, Siri Vinther, Rosangela Rea   +6 more
wiley   +1 more source

The Development of Sulfonylurea Compounds

Hans Journal of Medicinal Chemistry, 2014
openaire   +1 more source

Durability and Safety of Imeglimin as an Add‐On to DPP‐4 Inhibitors in Japanese Type 2 Diabetes: The 104‐Week FAMILIAR Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9101-9111, October 2026.
ABSTRACT Aims To evaluate the long‐term efficacy and safety of imeglimin added to dipeptidyl peptidase‐4 (DPP‐4) inhibitors in Japanese patients with type 2 diabetes, focusing on glycemic durability and safety in elderly patients over 104 weeks. Materials and Methods This multicenter, randomized, placebo‐controlled trial comprised a 24‐week double ...
Masashi Shimoda, Takeshi Osonoi, Masahiro Iwamoto, Hideaki Kaneto, Kohei Kaku   +4 more
wiley   +1 more source

Sulfonylurea Bioisosteres of Sulfonic Acid in JFD 00458-Based ST6GAL1 Inhibitors Enhance Membrane Permeability. [PDF]

ChemMedChem
Koraj N, Dangudubiyyam S, Betances-Mora AM, Faganeli E, Harduin-Lepers A, Angulo J, Nguyen TK, Bort-Griñó M, Hurtado-Guerrero R, Anderluh M.   +9 more
europepmc   +1 more source

Synthesis, Herbicidal Activity Evaluation, and Molecular Docking of Novel Acylthioureas as AHAS Inhibitors. [PDF]

Molecules
Jiang B, Chen X, He X, Chai Y, Wang Y, Li R.   +5 more
europepmc   +1 more source

Effectiveness of Telehealth Low‐Carbohydrate Intervention in Preventing Chronic Kidney Disease: A Real‐World, Retrospective, Matched Cohort Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9054-9068, October 2026.
ABSTRACT Background Lifestyle interventions targeting metabolic health may influence chronic kidney disease (CKD) risk, particularly among adults with type 2 diabetes and obesity. We evaluated real‐world associations between a telehealth‐delivered, individualized nutrition therapy program (VINT) and CKD incidence and progression compared with usual ...
Shaminie J. Athinarayanan, Petter Bjornstad, Priya V. Shanmugam, Thomas Weimbs, Adam J. Wolfberg, Jeff S. Volek, Jonathan Himmelfarb, Richard J. Johnson   +7 more
wiley   +1 more source